NICE Rejects Novartis’ Jakavi Again On Cost Grounds
This article was originally published in The Pink Sheet Daily
Executive Summary
Britain’s NICE has again turned down Novartis’ Jakavi for splenomegaly and myelofibrosis, citing confusion over survival benefit and high cost.